HLA相合外周血干细胞移植后移植物抗宿主病预防方案对巨细胞病毒再激活及疾病的影响
该回顾性研究比较了780例HLA相合外周血干细胞移植受者采用钙调磷酸酶抑制剂联合移植后环磷酰胺(PTCy;n=44)、吗替麦考酚酯(MMF;n=414)或甲氨蝶呤(MTX;n=322)预防移植物抗宿主病时巨细胞病毒(CMV)再激活及疾病情况,移植发生于2007年至2018年。多因素校正后,PTCy和MMF与早期(第≤100天)CMV再激活≥250 IU/mL风险增加相关;MMF组1年病毒载量曲线下面积最高。各组CMV疾病风险相似,1年内CMV疾病风险低。
要点
- PTCy和MMF与早期(第≤100天)CMV再激活≥250 IU/mL风险增加相关。
- MMF组1年病毒载量曲线下面积最高,平均差异为0.125单位(vs MTX组)。
- 各组CMV疾病风险相似,HLA相合外周血干细胞移植受者1年内CMV疾病风险低。
核心结论
- 尽管PTCy与早期CMV再激活风险增加相关,HLA相合外周血干细胞移植受者1年内CMV疾病风险低。
- MMF与移植后1年内总体CMV病毒载量较高相关。
- 不同免疫抑制药物的机制可能影响CMV再激活风险,但有效预防GVHD可能减少糖皮质激素暴露并随时间推移降低感染风险。
研究设计与样本
- 回顾性比较780例血清阳性且接受HLA相合外周血干细胞移植的患者,移植发生于2007年至2018年,CMV监测和管理遵循统一标准实践。
- GVHD预防方案为钙调磷酸酶抑制剂联合PTCy(n=44)、MMF(n=414)或MTX(n=322)。
- 比较不同阈值下CMV再激活的风险,对平均每日病毒载量拟合样条曲线并计算1年内曲线下面积(AUC)。
主要发现
- 多因素校正后,PTCy和MMF与早期(第≤100天)CMV再激活≥250 IU/mL风险增加相关。
- 1年病毒载量AUC在MMF组最高(平均差异=0.125单位 vs MTX组),PTCy与MTX组相似(平均差异=0.016单位 vs MTX组)。
- 各组CMV疾病风险相似。
- GVHD预防与CMV再激活对慢性GVHD风险无交互作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The kinetics of early and late cytomegalovirus (CMV) reactivation after hematopoietic cell transplantation using various methods of graft-versus-host-disease (GVHD) prophylaxis are poorly defined. We retrospectively compared CMV reactivation and disease among 780 seropositive patients given HLA-matched peripheral blood stem cell (PBSC) grafts and calcineurin inhibitor plus posttransplantation cyclophosphamide (PTCy; n = 44), mycophenolate mofetil (MMF; n = 414), or methotrexate (MTX; n = 322). Transplantation occurred between 2007 and 2018; CMV monitoring/management followed uniform standard practice. Hazards of CMV reactivation at various thresholds were compared. Spline curves were fit over average daily viral load and areas under the curve (AUC) within 1 year were calculated. PTCy and MMF were associated with an increased risk of early (day ≤100) CMV reactivation ≥250 IU/mL after multivariate adjustment. The viral load AUC at 1 year was highest with MMF (mean difference = 0.125 units vs MTX group) and similar between PTCy and MTX (mean difference = 0.016 units vs MTX group). CMV disease risk was similar across groups. There was no interaction between GVHD prophylaxis and CMV reactivation on chronic GVHD risk. Despite PTCy-associated increased risk of early CMV reactivation, the CMV disease risk by 1 year was low in HLA-matched PBSC transplant recipients. In contrast, MMF was associated with higher overall CMV viral burden in the 1 year posttransplant. Although different mechanisms of immunosuppressive agents may affect CMV reactivation risk, effective prevention of GVHD may reduce corticosteroid exposure and mitigate infection risk over time.
引用
- Ueda Oshima M, Xie H, Zamora D, et al. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. Blood Adv. 2023. PMID: 36595478. doi:10.1182/bloodadvances.2022009112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。